title: [Epilepsy and women's life: particularities of their management. Literature review].
abstract: Eight in 1,000 people in the world suffer from epilepsy, and 80 % of them are in the developing countries [1]. Sub-Saharan Africa and Latin America have higher median prevalence's 15.4 % and 12.4 %, respectively, compared to the prevalence in Europe, 5.4 %, and in North America, 5-10 % [2]. On this epidemiological inequality overlays a considerable disparity in the quality of care given to people with epilepsy, between developed and developing countries, and rural and urban areas. In this context, one of the most controversial subject regarding epilepsy is the care given to epileptic patients and their offspring. In fact, being a woman with epilepsy is not as being a man. The specific concerns about women with epilepsy are essentially sexual development, contraception, reproduction, fertility, and anatomic and cognitive teratogenicity of anti-epileptic drugs. The awareness campaign of women with epilepsy starts from puberty until menopause. About one third of epileptic women experience variations in their disease linked to menses, probably due to the neurotoxicity of oestrogens (not counterbalanced by progestatives). The problem with the teratogenicity of anti-epileptic drugs is not resolved yet despite the availability of new molecules. A close collaboration between health practitioners (obstetricians and neurologists) and an awareness of health professionals are essential for a global care of pregnant epileptic women or at age to conceive.
authors: Service de neurologie, CHU Gabriel Toure BP, Bamako, Mali.
authors: Y
authors: Y
authors: Maiga
authors: C
authors: C
authors: Napon
authors: C
authors: C
authors: Kuate Tegueu
authors: Y
authors: Y
authors: Traore
authors: I
authors: I
authors: Tekete
authors: N
authors: N
authors: Mounkoro
authors: A
authors: A
authors: Dolo
authors: M Y
authors: MY
authors: Maiga
authors: H A
authors: HA
authors: Traore
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000209:etiology / Q000517:prevention & control; D017677:Age Distribution; D000927:Anticonvulsants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D003278:Contraceptives, Oral, Hormonal / Q000493:pharmacokinetics; D003906:Developing Countries; D019468:Disease Management; D004347:Drug Interactions; D004827:Epilepsy / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*; D005260:Female; D012739:Gonadal Steroid Hormones / Q000493:pharmacokinetics / Q000502:physiology; D006297:Health Services Accessibility; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000209:etiology / Q000517:prevention & control; D008302:Mali / Q000453:epidemiology; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D015995:Prevalence; D055703:Reproductive Physiological Phenomena / Q000187:drug effects; D017678:Sex Distribution; D016387:Women's Health
chemical_list: D000927:Anticonvulsants; D003278:Contraceptives, Oral, Hormonal; D012739:Gonadal Steroid Hormones